This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsGreenLight Biosciences Holdings（GRNA）株式概要GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. 詳細GRNA ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績0/6財務の健全性4/6配当金0/6報酬収益は年間70.67%増加すると予測されています リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい今後3年間の収益は年平均1%減少すると予測されている。 現在は利益が出ておらず、今後3年間で利益が出る見込みはない 過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るGRNA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.3068.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-307m150m2016201920222025202620282031Revenue US$149.8mEarnings US$27.6mAdvancedSet Fair ValueView all narrativesGreenLight Biosciences Holdings 競合他社Dyadic InternationalSymbol: NasdaqCM:DYAIMarket cap: US$30.9mElutiaSymbol: NasdaqCM:ELUTMarket cap: US$43.8mAligos TherapeuticsSymbol: NasdaqCM:ALGSMarket cap: US$33.1mPrecision BioSciencesSymbol: NasdaqCM:DTILMarket cap: US$167.7m価格と性能株価の高値、安値、推移の概要GreenLight Biosciences Holdings過去の株価現在の株価US$0.3052週高値US$5.9052週安値US$0.18ベータ1.441ヶ月の変化3.20%3ヶ月変化-6.08%1年変化-85.25%3年間の変化n/a5年間の変化n/aIPOからの変化-96.94%最新ニュースお知らせ • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .お知らせ • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.お知らせ • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.お知らせ • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.最新情報をもっと見るRecent updatesお知らせ • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .お知らせ • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.お知らせ • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.お知らせ • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.27 loss per share (vs US$9.86 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share. Net loss: US$38.2m (loss widened 14% from 3Q 2021). Revenue is forecast to grow 121% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.Seeking Alpha • Oct 12GreenLight Biosciences cutting 25% of staff as part of realignmentGreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.Recent Insider Transactions • Aug 17Independent Director recently bought US$250k worth of stockOn the 11th of August, Matthew Walker bought around 64k shares on-market at roughly US$3.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.28 loss in 2Q 2021)Second quarter 2022 results: US$0.42 loss per share (down from US$0.28 loss in 2Q 2021). Net loss: US$51.9m (loss widened 91% from 2Q 2021).お知らせ • Aug 13GreenLight Biosciences Holdings announced that it expects to receive $109.149981 million in funding from a group of investorsGreenLight Biosciences Holdings announced a private placement of 27,844,383 common shares at a price per share of $3.92 for gross proceeds of $109,149,981 on August 12, 2022. The transaction will include participation from accredited investors, existing institutional investors and new investors including Cummings Foundation, Inc., Endowment Arm, the FTX Foundation, Insud Pharma S.L.U., Rivas Capital LLC, Sigmas Group, SymBiosis Capital Management LLC, returning investors S2G Ventures, Bnp Paribas Funds - Ecosystem Restoration; a fund managed by BNPP Asset Management Luxembourg, Continental Grain Company Corp., Cormorant Asset Management, LP, Fall Line Capital, LLC, Morningside Ventures Limited, and certain directors and executive officers of the company.Seeking Alpha • Aug 12GreenLight Biosciences launches $109M in financingGreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.お知らせ • Aug 02GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 VaccineGreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability. GreenLight's process—from drug substance and lipid nanoparticle formulation to bulk drug product—can be completed in the same facility, an important capability. GreenLight's mRNA synthesis reaction had a titer of 12g/L at commercial scale and produced 650g of mRNA. The company's RNA platform allowed GreenLight to move from conceptualizing an mRNA vaccine to delivering released clinical trial material in less than two years. With the demonstration at Samsung, and with GreenLight's Covid booster vaccine clinical trial expected to start in 2022, GreenLight would be capable of supplying mRNA vaccine at a commercial scale.Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Aug 01GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccineGreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.Board Change • Jul 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 18First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 loss in 1Q 2021)First quarter 2022 results: US$0.34 loss per share (down from US$0.27 loss in 1Q 2021). Net loss: US$38.2m (loss widened 49% from 1Q 2021).Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Apr 05GreenLight Biosciences: Synthesizing Cell-Free RNAGreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.お知らせ • Mar 30GreenLight Biosciences Appoints Barney Graham as Human Health Scientific Advisory BoardGreenLight Biosciences announced Barney Graham to its Human Health Scientific Advisory Board. The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service. Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure.お知らせ • Feb 08GreenLight Biosciences Holdings Announces Management ChangesOn February 2, 2022, Environmental Impact Acquisition Corp. (ENVI), consummated the previously announced business combination with GreenLight Biosciences Inc. (GreenLight), pursuant to the terms of the business combination agreement, dated August 9, 2021 (the Business Combination Agreement), among ENVI, GreenLight and Honey Bee Merger Sub Inc. (“Merger Sub). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into GreenLight, with GreenLight surviving the merger as a wholly owned subsidiary of ENVI (the Merger or Business Combination). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (GreenLight Holdings) and became a public benefit corporation. Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Daniel Coyne, Marc Marano, Deval L. Patrick, David Brewster and Dean Seavers ceased serving as a director of GreenLight Holdings, and each of Daniel Coyne and Marc Marano ceased serving as an executive officer of GreenLight Holdings.Board Change • Feb 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Observer Colin Steen was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元GRNAUS BiotechsUS 市場7D0.4%1.3%1.7%1Y-85.2%31.1%25.1%株主還元を見る業界別リターン: GRNA過去 1 年間で31.1 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: GRNAは、過去 1 年間で25.1 % のリターンを上げたUS市場を下回りました。価格変動Is GRNA's price volatile compared to industry and market?GRNA volatilityGRNA Average Weekly Movement16.1%Biotechs Industry Average Movement10.5%Market Average Movement7.2%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.1%安定した株価: GRNAの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: GRNAの weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008n/aAndrey Zarurgreenlightbiosciences.comもっと見るGreenLight Biosciences Holdings 基礎のまとめGreenLight Biosciences Holdings の収益と売上を時価総額と比較するとどうか。GRNA 基礎統計学時価総額US$45.43m収益（TTM）-US$157.32m売上高(TTM)US$10.34m4.4xP/Sレシオ-0.3xPER（株価収益率GRNA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GRNA 損益計算書（TTM）収益US$10.34m売上原価US$129.70m売上総利益-US$119.35mその他の費用US$37.96m収益-US$157.32m直近の収益報告Mar 31, 2023次回決算日該当なし一株当たり利益（EPS）-1.04グロス・マージン-1,153.96%純利益率-1,521.00%有利子負債／自己資本比率111.6%GRNA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/07/25 19:59終値2023/07/21 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GreenLight Biosciences Holdings 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Robert BurlesonCanaccord Genuity
お知らせ • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .
お知らせ • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.
Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.
お知らせ • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.
お知らせ • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
お知らせ • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .
お知らせ • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.
Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.
お知らせ • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.
お知らせ • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.27 loss per share (vs US$9.86 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share. Net loss: US$38.2m (loss widened 14% from 3Q 2021). Revenue is forecast to grow 121% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Seeking Alpha • Oct 12GreenLight Biosciences cutting 25% of staff as part of realignmentGreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.
Recent Insider Transactions • Aug 17Independent Director recently bought US$250k worth of stockOn the 11th of August, Matthew Walker bought around 64k shares on-market at roughly US$3.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.28 loss in 2Q 2021)Second quarter 2022 results: US$0.42 loss per share (down from US$0.28 loss in 2Q 2021). Net loss: US$51.9m (loss widened 91% from 2Q 2021).
お知らせ • Aug 13GreenLight Biosciences Holdings announced that it expects to receive $109.149981 million in funding from a group of investorsGreenLight Biosciences Holdings announced a private placement of 27,844,383 common shares at a price per share of $3.92 for gross proceeds of $109,149,981 on August 12, 2022. The transaction will include participation from accredited investors, existing institutional investors and new investors including Cummings Foundation, Inc., Endowment Arm, the FTX Foundation, Insud Pharma S.L.U., Rivas Capital LLC, Sigmas Group, SymBiosis Capital Management LLC, returning investors S2G Ventures, Bnp Paribas Funds - Ecosystem Restoration; a fund managed by BNPP Asset Management Luxembourg, Continental Grain Company Corp., Cormorant Asset Management, LP, Fall Line Capital, LLC, Morningside Ventures Limited, and certain directors and executive officers of the company.
Seeking Alpha • Aug 12GreenLight Biosciences launches $109M in financingGreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.
お知らせ • Aug 02GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 VaccineGreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability. GreenLight's process—from drug substance and lipid nanoparticle formulation to bulk drug product—can be completed in the same facility, an important capability. GreenLight's mRNA synthesis reaction had a titer of 12g/L at commercial scale and produced 650g of mRNA. The company's RNA platform allowed GreenLight to move from conceptualizing an mRNA vaccine to delivering released clinical trial material in less than two years. With the demonstration at Samsung, and with GreenLight's Covid booster vaccine clinical trial expected to start in 2022, GreenLight would be capable of supplying mRNA vaccine at a commercial scale.
Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Aug 01GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccineGreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.
Board Change • Jul 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 18First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 loss in 1Q 2021)First quarter 2022 results: US$0.34 loss per share (down from US$0.27 loss in 1Q 2021). Net loss: US$38.2m (loss widened 49% from 1Q 2021).
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Apr 05GreenLight Biosciences: Synthesizing Cell-Free RNAGreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.
お知らせ • Mar 30GreenLight Biosciences Appoints Barney Graham as Human Health Scientific Advisory BoardGreenLight Biosciences announced Barney Graham to its Human Health Scientific Advisory Board. The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service. Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure.
お知らせ • Feb 08GreenLight Biosciences Holdings Announces Management ChangesOn February 2, 2022, Environmental Impact Acquisition Corp. (ENVI), consummated the previously announced business combination with GreenLight Biosciences Inc. (GreenLight), pursuant to the terms of the business combination agreement, dated August 9, 2021 (the Business Combination Agreement), among ENVI, GreenLight and Honey Bee Merger Sub Inc. (“Merger Sub). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into GreenLight, with GreenLight surviving the merger as a wholly owned subsidiary of ENVI (the Merger or Business Combination). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (GreenLight Holdings) and became a public benefit corporation. Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Daniel Coyne, Marc Marano, Deval L. Patrick, David Brewster and Dean Seavers ceased serving as a director of GreenLight Holdings, and each of Daniel Coyne and Marc Marano ceased serving as an executive officer of GreenLight Holdings.
Board Change • Feb 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Observer Colin Steen was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
